Finanzen von Spruce Biosciences, Inc (SPRB)SPRBSpruce Biosciences, Inc

Evaluating the bottom line, Spruce Biosciences, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -105.98%, provide a clear picture of how effectively SPRB converts its operational activities into shareholder value.

In the context of the broader market, SPRB competes directly with industry leaders such as CRBU and HUMA. With a market capitalization of $168.56M, it holds a significant position in the sector. When comparing efficiency, SPRB's gross margin of N/A stands against CRBU's 100.00% and HUMA's -203.20%. Such benchmarking helps identify whether Spruce Biosciences, Inc. is trading at a premium or discount relative to its financial performance.

Spruce Biosciences has experienced significant revenue fluctuations, with total revenue of $602,000 in Q3 2024, but no revenue reported in subsequent quarters. The company has consistently reported negative net income, with a net loss of $16,229,000 in Q2 2026, demonstrating ongoing financial struggles.